Fenfluramine Hydrochloride
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout Fenfluramine Hydrochloride
Fenfluramine Hydrochloride is a pre-clinical stage product being developed by UCB for Dravet Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03780127. Target conditions include Dravet Syndrome.
What happened to similar drugs?
2 of 12 similar drugs in Dravet Syndrome were approved
Approved (2) Terminated (3) Active (7)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03780127 | Pre-clinical | Completed |
Competing Products
15 competing products in Dravet Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 40 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 32 |
| ZX008 0.2 to 0.8 mg/kg/day + Cannabidiol | UCB | Phase 1 | 29 |
| fenfluramine | UCB | Approved | 50 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 40 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 40 |
| fenfluramine | UCB | Phase 3 | 44 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 40 |
| Clobazam | Lundbeck | Phase 3 | 29 |
| Clobazam + Placebo | Lundbeck | Phase 3 | 29 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Approved | 47 |
| zorevunersen | Stoke Therapeutics | Phase 3 | 41 |
| STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending Doses | Stoke Therapeutics | Phase 1/2 | 26 |
| zorevunersen (STK-001) | Stoke Therapeutics | Phase 2 | 33 |
| Clemizole HCl + Placebo | Harmony Biosciences | Phase 3 | 41 |